- Home
- PRTC vs ANGO Comparison
PRTC vs ANGO Comparison
Compare PRTC & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- ANGO
- Stock Information
- Founded
- PRTC 2015
- ANGO 1988
- Country
- PRTC United States
- ANGO United States
- Employees
- PRTC N/A
- ANGO N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- ANGO Medical/Dental Instruments
- Sector
- PRTC Health Care
- ANGO Health Care
- Exchange
- PRTC Nasdaq
- ANGO Nasdaq
- Market Cap
- PRTC 428.7M
- ANGO 400.8M
- IPO Year
- PRTC N/A
- ANGO 2004
- Fundamental
- Price
- PRTC $16.16
- ANGO $12.07
- Analyst Decision
- PRTC
- ANGO Strong Buy
- Analyst Count
- PRTC 0
- ANGO 3
- Target Price
- PRTC N/A
- ANGO $19.33
- AVG Volume (30 Days)
- PRTC 4.3K
- ANGO 453.2K
- Earning Date
- PRTC 08-28-2025
- ANGO 10-02-2025
- Dividend Yield
- PRTC N/A
- ANGO N/A
- EPS Growth
- PRTC N/A
- ANGO N/A
- EPS
- PRTC 0.20
- ANGO N/A
- Revenue
- PRTC $6,391,000.00
- ANGO $300,718,000.00
- Revenue This Year
- PRTC N/A
- ANGO $8.18
- Revenue Next Year
- PRTC N/A
- ANGO $5.15
- P/E Ratio
- PRTC $7.76
- ANGO N/A
- Revenue Growth
- PRTC 1265.60
- ANGO 2.73
- 52 Week Low
- PRTC $13.30
- ANGO $6.63
- 52 Week High
- PRTC $24.99
- ANGO $13.50
- Technical
- Relative Strength Index (RSI)
- PRTC 41.62
- ANGO 54.49
- Support Level
- PRTC $16.22
- ANGO $11.53
- Resistance Level
- PRTC $17.69
- ANGO $12.84
- Average True Range (ATR)
- PRTC 0.44
- ANGO 0.40
- MACD
- PRTC -0.16
- ANGO -0.02
- Stochastic Oscillator
- PRTC 1.42
- ANGO 48.15
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.